Bio-Rad Laboratories, Inc. Stock NYSE
Stocks
BIO.B
US0905721082
Medical Equipment, Supplies & Distribution
|
Market Closed -
NYSE
16:10:00 2026-08-20 EDT
|
5-day change | 1st Jan Change | ||
| 365.08 USD | +8.33% |
|
-.--% | +17.50% |
| Market Cap | 9.78B 8.77B 8.17B 7.41B 13.97B 937B 14.06B 98.18B 38.42B 483B 36.75B 35.94B 1,552B | P/E 2026 * |
44x | P/E 2027 * | 43x |
|---|---|---|---|---|---|
| Enterprise Value | 9.04B 8.1B 7.54B 6.84B 12.9B 865B 12.99B 90.67B 35.48B 446B 33.93B 33.19B 1,433B | EV / Sales 2026 * |
3.52x | EV / Sales 2027 * | 3.36x |
| Free-Float |
60.17% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| BIO.B | Delayed | |
Deutsche Boerse AG
| BUW | Delayed |
Last Transcript: Bio-Rad Laboratories, Inc.
| 1 day | +8.33% | ||
| 3 months | +22.30% | ||
| 6 months | +31.80% | ||
| Current year | +17.50% |
| Current year | 244.54 |  | 365.08 |
| 1 year | 244.54 | | 365.08 |
| 3 years | 0 | | 365.08 |
| 5 years | 0 | | 784.4 |
| 10 years | 0 | | 818.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
Norman Schwartz
CEO | Chief Executive Officer | 76 | 2002-12-31 |
| President | 61 | 2024-09-08 | |
Roop Lakkaraju
DFI | Director of Finance/CFO | 55 | 2024-04-14 |
| Director | Title | Age | Since |
|---|---|---|---|
Norman Schwartz
CHM | Chairman | 76 | 2011-12-31 |
Jeffrey Edwards
BRD | Director/Board Member | 73 | 2017-04-24 |
Gregory Hinckley
BRD | Director/Board Member | 79 | 2017-04-24 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +8.33% | -.--% | - | - | 9.78B | |
| +2.23% | +1.72% | -23.20% | +12.89% | 172B | |
| +3.90% | +4.50% | -3.69% | +28.95% | 113B | |
| +1.90% | -0.92% | -22.49% | +11.33% | 106B | |
| +0.27% | +1.56% | -46.32% | -11.83% | 75.31B | |
| +0.37% | +3.22% | +2.22% | +73.30% | 61.8B | |
| +0.12% | +3.62% | +15.06% | +62.75% | 52.93B | |
| +2.80% | +4.55% | +1.25% | -26.52% | 50.05B | |
| +1.15% | -0.59% | -14.97% | +22.33% | 40.81B | |
| -1.38% | -0.11% | - | - | 31.81B | |
| Average | +1.51% | +2.43% | -11.52% | +21.65% | 78.29B | |
| Weighted average by Cap. | +1.09% | +2.34% | -14.73% | +19.69% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.57B 2.3B 2.14B 1.95B 3.67B 246B 3.69B 25.78B 10.09B 127B 9.65B 9.44B 408B | 2.62B 2.35B 2.19B 1.99B 3.75B 251B 3.77B 26.33B 10.3B 129B 9.86B 9.64B 416B |
| Net income | 225M 202M 188M 170M 321M 21.53B 323M 2.26B 883M 11.09B 844M 826M 35.66B | 230M 206M 192M 174M 328M 22B 330M 2.31B 902M 11.33B 863M 844M 36.43B |
| Net Debt | -749M -671M -625M -567M -1.07B -71.73B -1.08B -7.52B -2.94B -36.95B -2.81B -2.75B -119B | -965M -865M -806M -731M -1.38B -92.45B -1.39B -9.69B -3.79B -47.62B -3.63B -3.55B -153B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-12 | US$0.000000 | - | 4 |
| 26-10-09 | US$0.000000 | - | 8 |
| 26-10-08 | US$0.000000 | - | 11 |
| 26-10-07 | US$0.000000 | - | 13 |
| 26-10-06 | US$0.000000 | - | 10 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BIO Stock
- BIO.B Stock
Select your edition
All financial news and data tailored to specific country editions
